Tirzepatide ZPHC — 15 mg (1 vial × 15 mg)

Tirzepatide — ZPHC
1 lyophilised vial × 15 mg (total 15 mg) + sterile diluent

• Dual incretin agonist: activates GLP-1 & GIP pathways for appetite suppression and improved metabolic markers.
• Weight-management research: supports reduced caloric intake, enhanced glycaemic control and improved body-composition outcomes.
• High-purity formulation: ≥ 98.9% purity (HPLC); produced under GMP & ISO 17034:2016 with ZPHC scratch-code verification.
• Reconstitution: add sterile diluent provided; swirl gently until dissolved. Store at 2–8 °C.
• For research use only: analytical reference material; not intended for human use.
• Cold-chain packed • tamper-evident vial • discreet, tracked worldwide delivery.